Key result
Elevated GDF15 is linked to major depression and insulin resistance, predicting persistent depressive symptoms.
Why the study?
Major depressive disorder is linked to insulin resistance, and while the stress-induced cytokine GDF15 may mediate this relationship by connecting peripheral to central energy metabolism, its role in MDD was unclear.
Case-Control (n=373)
GDF15 is elevated in both major depressive disorder and insulin resistance and predicts symptom persistence in MDD, positioning it as a mechanistic biomarker at the interface of psychiatric and metabolic health.
Answers are grounded in this paper and cite their sources.
GDF15 may aid risk stratification in MDD with insulin resistance; leaves open causal roles and clinical utility pending prospective validation.
OBJECTIVE: Major depressive disorder (MDD) is linked to insulin resistance, which is associated with increased risk, chronicity, and poor treatment response in depression. Growth differentiation factor 15 (GDF15), a stress-induced cytokine linking peripheral to central energy metabolism, may mediate this link, but its role in MDD is unclear. The authors assessed associations of MDD and insulin resistance with GDF15; links between GDF15, symptoms, and stress; and whether baseline GDF15 levels predict symptom persistence. METHODS: In this preregistered secondary analysis, 190 participants with MDD and 183 control participants provided blood, underwent interviews, and completed questionnaires. GDF15 values were log-transformed and analyzed with linear models. The association between GDF15 and depression severity was validated in an independent cohort of medication-free MDD patients (N=168). RESULTS: Both MDD diagnosis and insulin resistance were significantly associated with elevated GDF15 (adjusted for age and sex). Across all participants, elevated GDF15 was significantly associated with greater depressive severity, childhood trauma, and perceived stress. In stratified analyses, the association with depression severity and perceived stress was significant only in healthy control subjects. In MDD patients, baseline GDF15 was associated with persistence of symptoms across time. In the second independent sample of medication-free MDD patients, depression severity was significantly associated with GDF15. CONCLUSIONS: GDF15 is elevated in MDD and insulin resistance, indicating convergent stress-energy pathway activation, and in MDD higher GDF15 predicted symptom persistence. These findings position GDF15 as a mechanistic biomarker at the interface of psychiatric and metabolic health and reinforce the need for integrated care of metabolic and mental health.
No takes yet. Share an insight, caveat, or question.
Aichholzer et al. (2026) conducted a case-control in Major depressive disorder and insulin resistance (n=373). Major depressive disorder, insulin resistance, and elevated baseline GDF15 vs. Healthy control participants (n=183) was evaluated on Log-transformed GDF15 levels and persistence of depressive symptoms. Major depressive disorder (n=190) and insulin resistance were significantly associated with elevated GDF15 compared with healthy controls (n=183), and baseline GDF15 predicted symptom persistence.
Synapse has enriched 10 related papers. Consider them for comparative context: